Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Cost-effectiveness of nivolumab in the treatment of head and neck cancer.

Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M; Swiss Group of Clinical Cancer Research (SAKK).

Oral Oncol. 2018 Dec;87:104-110. doi: 10.1016/j.oraloncology.2018.10.032. Epub 2018 Oct 30.

PMID:
30527224
2.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10.

PMID:
30104008
3.

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.

Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M; Swiss Group for Clinical Cancer Research (SAKK).

Ann Surg Oncol. 2018 Sep;25(9):2632-2640. doi: 10.1245/s10434-018-6556-9. Epub 2018 Jun 8.

PMID:
29948418
4.

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Jun;163(3):635. doi: 10.1007/s10549-017-4209-5. Epub 2017 Mar 21. No abstract available.

PMID:
28321586
5.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
6.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research.

J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14.

7.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2016 Oct 10;16(1):780.

8.

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-57. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

PMID:
27277747
9.

Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).

Matter-Walstra K, Schwenkglenks M, Betticher D, von Moos R, Dietrich D, Baertschi D, Koeberle D.

Clin Colorectal Cancer. 2016 Dec;15(4):314-320.e2. doi: 10.1016/j.clcc.2016.03.002. Epub 2016 Mar 31.

PMID:
27117056
10.

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Konzelmann I, Mousavi M, Clough-Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12453. Epub 2016 Feb 9.

PMID:
26856977
11.

Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.

Schwenkglenks M, Matter-Walstra K.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):207-19. doi: 10.1586/14737167.2016.1146594. Epub 2016 Feb 18. Review.

PMID:
26808097
12.

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.

Br J Dermatol. 2016 Feb;174(2):463. doi: 10.1111/bjd.14279. Epub 2016 Jan 20. No abstract available.

PMID:
26787297
13.

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.

Br J Dermatol. 2015 Dec;173(6):1462-70. doi: 10.1111/bjd.14152. Epub 2015 Nov 7.

14.

End-of-life costs of medical care for advanced stage cancer patients.

Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, Jakovljević M.

Vojnosanit Pregl. 2015 Apr;72(4):334-41. Erratum in: Vojnosanit Pregl. 2015 Jul;72(7):656. Gutzwiller, Florian [corrected to Gutzwiller, Florian S].

PMID:
26040179
15.

Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation.

Matter-Walstra KW, Greiner M, Cusini A, Schiesser M, Ledergerber B, Fehr T, Mueller NJ.

Transpl Infect Dis. 2015 Jun;17(3):342-9. doi: 10.1111/tid.12379. Epub 2015 May 19.

PMID:
25816700
16.

Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma.

Jakovljevic M, Gutzwiller F, Schwenkglenks M, Milovanovic O, Rancic N, Varjacic M, Stojadinovic D, Dagovic A, Matter-Walstra K.

J BUON. 2014 Oct-Dec;19(4):1111-20.

PMID:
25536624
17.

Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols.

Jakovljevic M, Gutzwiller FS, Schwenkglenks M, Milovanovic O, Rancic N, Varjacic M, Stojadinovic D, Dagovic A, Matter-Walstra K.

Value Health. 2014 Nov;17(7):A629. doi: 10.1016/j.jval.2014.08.2247. Epub 2014 Oct 26. No abstract available.

18.

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr K, Szucs T, Pestalozzi BC, Schwenkglenks M.

Oncology. 2015;88(1):18-27. doi: 10.1159/000367629. Epub 2014 Sep 26.

19.

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr KM, Szucs TD, Schwenkglenks M, Pestalozzi BC.

BMC Cancer. 2014 May 1;14:306. doi: 10.1186/1471-2407-14-306.

20.

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, Schwenkglenks M.

Pharmacoeconomics. 2014 Jun;32(6):591-9. doi: 10.1007/s40273-014-0151-0.

Supplemental Content

Loading ...
Support Center